A recent survey shows that some patients have greater concerns about automatic substitution of biosimilar products than they do about the high cost of biologic drugs.
A recent survey shows that some patients have greater concerns about automatic substitution of biosimilar products than they do about the high cost of biologic drugs.
The survey, conducted by the Canadian group Consumer Advocare Network from May to June 2017, assessed the views of 588 patients, half of whom were currently taking a biologic medicine. The patients had been diagnosed with diseases including arthritis, diabetes, gastrointestinal disorders, cancers, and rare diseases. The survey found the following:
“The bottom line is that patients want to be sure that the biologic medicines they are taking have been tested for their condition, they have a choice as to which biologic is prescribed, and what they are prescribed is what they get,” Consumer Advocare Network said in its press release announcing the survey results.
Automatic substitution is the norm in Canada, where lower-cost products may be automatically substituted for reference products. In the United States, however, 33 states and Puerto Rico have taken legislative action concerning biosimilar substitution, with most states prohibiting automatic substitution and protecting the physician-patient relationship by ensuring communication concerning substitution of a biosimilar for a reference drug.
Despite patients’ concerns about being moved to biosimilars against their will, and despite legislative action seeking to leave choices concerning the use of biosimilars in the hands of physicians, other factors—such as formulary design—could push patients from reference products to biosimilars.
This week, Express Scripts, a leading pharmacy benefit manager (PBM), released its 2018 National Preferred Formulary. This updated formulary introduces several drug exclusions, including replacing filgrastim (Neupogen) with its competitors, TBO-filgrastim (Granix) and the biosimilar fligrastim-sndz (Zarxio).
The company notes that it is also considering changes to drugs treating inflammatory conditions, and that it could expand the list of excluded products to include such treatments when it releases its final 2018 list on or before September 15, 2017. It remains to be seen whether Merck and Samsung Bioepis’ newly launched infliximab biosimilar, Renflexis (introduced at a 35% discount to the reference Remicade), could push the originator product off formularies, leaving patients and providers with fewer, yet cheaper, options for biologic treatment.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.